ALK-Abelló is a global, research-driven pharmaceutical company specializing in the diagnosis and treatment of allergies. With over a century of experience, ALK is a world leader in allergy immunotherapy (AIT), a unique treatment that not only reduces allergic symptoms but also addresses the underlying cause of the allergy. The company offers a comprehensive portfolio of AIT products, including sublingual immunotherapy tablets (SLIT-tablets) and subcutaneous immunotherapy (SCIT). ALK is committed to innovation, continuously investing in R&D to develop new and improved allergy treatments and diagnostic tools, aiming to improve the quality of life for millions of people suffering from allergies worldwide.
The Hørsholm headquarters serves as the central hub for ALK's global operations, including corporate management, strategic planning, research and development leadership, global marketing, and administrative functions.
The headquarters is part of a modern campus in the DTU Science Park, fostering collaboration and innovation, and includes advanced research laboratories and office spaces reflecting the company's scientific focus.
The work culture emphasizes scientific excellence, innovation, patient-centricity, and collaboration, typical of a research-driven pharmaceutical company. It also reflects Danish workplace values of trust, work-life balance, and employee well-being.
The Hørsholm HQ is the nerve center for ALK's global strategy and R&D in allergy immunotherapy, driving its mission. Its location in Denmark positions it within a strong life sciences cluster.
ALK supports its global operations through a network of research and development facilities, state-of-the-art manufacturing sites in Denmark, France, Spain and the USA, and sales and marketing offices across Europe, North America, and key international markets including China. This global infrastructure enables ALK to develop, produce, and distribute its allergy immunotherapy treatments and diagnostics to patients in over 40 countries worldwide. Key functions supported globally include R&D, clinical trials, manufacturing, quality assurance, regulatory affairs, sales, marketing, and medical affairs.
Bøge Alle 1
Hørsholm
Hovedstaden
Denmark
Address: 1700 Royston Lane, Round Rock, TX 78664, USA
Supports the commercialization, distribution, and market access of allergy immunotherapy products for patients in the United States and North America.
Address: Site de Vandeuil, 161 rue des Montepillois, 51140 Vandeuil, France
Focuses on the large-scale production and quality control of allergy treatments, ensuring consistent supply for European healthcare providers and patients.
Address: Miguel Fleta, 19, 28037 Madrid, Spain
Manages sales, marketing, distribution, medical affairs, and regulatory activities for ALK's products in Spain, a key European market for the company.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ALK' leadership includes:
ALK has been backed by several prominent investors over the years, including:
ALK-Abelló has made key appointments to its executive team in the past 12 months, notably strengthening its finance, commercial, and product supply leadership. This includes the permanent appointment of its CFO and new EVPs for Commercial Operations Europe and Product Supply, alongside one departure.
Discover the tools ALK uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
ALK-Abelló likely utilizes standardized email formats for its employees. Common corporate patterns involve combinations of an employee's first name, last name, or initials. Specific departmental or regional variations might exist.
Commonly attempted formats include [first_initial][last_name]@alk.net (e.g., jdoe@alk.net) or [first_name].[last_name]@alk.net (e.g., jane.doe@alk.net). Some specific internal contacts might use an initials-based system (e.g., xxYY@alk.net).
Format
jdoe@alk.net or jane.doe@alk.net
Example
65%
Success rate
GlobeNewswire • May 7, 2024
ALK reported strong Q1 2024 financial results with 13% revenue growth (14% in local currencies), driven by broad-based growth, especially in tablet sales which grew by 22%. The EBIT margin reached 26%. The company maintained its full-year financial outlook for 2024....more
GlobeNewswire • April 10, 2024
ALK announced that its allergy immunotherapy tablet (AIT) franchise gained further market share in its European key markets during the first quarter of 2024. This growth highlights the increasing adoption of ALK's tablet-based treatments for respiratory allergies....more
GlobeNewswire • February 7, 2024
ALK reported its full-year 2023 results, meeting its financial outlook with revenue growth of 11% in local currencies. The company also provided an outlook for 2024, anticipating continued revenue growth and significantly improved earnings....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ALK, are just a search away.